InspireMD, Inc.
NSPRHealthcareNASDAQMedical Devices · Last scanned Oct 26, 2026
Scan Results
Daily timeframeInspireMD, Inc., a medical device company, focuses on the development and commercialization of products for the treatment of carotid artery disease and other vascular conditions in the United States,. At a $20.9M market cap, InspireMD, Inc. ranks as a micro-cap company within healthcare. It offers MicroNet, a biocompatible polymer mesh material for medical implants, as well as for treating plaque prolapse and embolization; CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Carotid Stent System; and SwitchGuard neuroprotection system to provide flow reversal of cerebral protection in carotid interventions, as well as treating acute stroke with tandem lesions.
Market Cap
$20.9M
Beta
0.83
P/E (TTM)
—
P/E (Fwd)
-0.93
EPS (TTM)
$-0.62
EPS (Fwd)
$-0.48
ROE
-202.8%
ROA
-85.9%
Cash
$30.4M
Total Debt
$3.0M
Free CF
-$23.1M
52W Change
-80.1%
Annual Financials
Cash vs Debt
Where NSPR stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, NSPR finished 53.19% below its 150-day moving average ($0.94) and 61.06% below its 200-day moving average ($1.13). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is NSPR overbought or oversold?
At the October 20, 2026 close, NSPR's RSI(14) was 16.2, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $30.4M in cash and $3.0M in debt, NSPR maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$23.1M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -202.8% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $5.2M (2022) to $9.0M (2025), reflecting a 74% increase over the period.
With cash comfortably exceeding debt, NSPR has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for InspireMD, Inc. and its sector.